What are the rules of investing in science-based innovation? How much long-term thinking does it take to get through tightened markets and economic downturns? These questions are at the core of Vicki L. Sato´s research, who is a Professor of Management Practice in the Technology and Operations Management unit at Harvard Business School. In addition, she is also an advisor to Atlas Venture´s life sciences team.  » Read more...

“Start-up Nation” by Dan Senor and Saul Singer addresses the trillion-dollar question: How is it that a country of a mere 7.1 million people has per capita venture capital investments 2.5 times greater than in the US (more than 30 times greater than in Europe), the highest density of high tech start-ups in the world (1 for every 1,844 inhabitant) and more companies listed at NASDAQ than all companies from the entire European continent?  » Read more...

MediGene AG (Frankfurt, Prime Standard, MDG, TecDAX) has announced the sale of full European marketing and distribution rights to Eligard^® (leuprolide acetate, for the treatment of hormone-dependent prostate cancer) to Astellas Pharma Europe Ltd. (London, “Astellas”), previously MediGene’s European marketing partner for Eligard^®. Astellas will make one-off payments totalling EUR 25 million, while MediGene remains entitled to royalties. There will be no further costs to MediGene. The sales price reflects the full NPV of all future Eligard® revenues while allowing MediGene to benefit from continued Eligard® growth. For more information, please see the full press release.
 » Read more...

In several clinical trials, antibody company Micromet has demonstrated outstanding efficacy and safety of its bispecific BiTE antibodies which come with two binding sites: one for a cancer target and a second one for a T cell. As a result, T cells are recruited and guided directly to the tumor cell, initiating cancer cell death in a serial fashion.  » Read more...